CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 360 resultados LastUpdate Última actualización 29/09/2022 [13:52:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



Página1 de 15 nextPage   por página


KIT FOR DETECTING NOVEL CORONAVIRUS, AND PREPARATION METHOD THEREFOR AND DETECTION METHOD THEREFOR

NºPublicación: EP4063865A1 28/09/2022

Solicitante:

BEIJING JINWOFU BIOENGINEERING TECH CO LTD [CN]

Resumen de: EP4063865A1

The present discosure discloses a detection kit and a preparation method thereof and a detection method for novel coronavirus, and relates to the technical field of biomedicine, including antigen test strip; the antigen test strip includes a substrate, bibulous paper, immune nitrocellulose membrane, and immune microsphere pad; the immune microsphere pad, the immune nitrocellulose membrane and the bibulous paper are pasted on the substrate; the immune microsphere pad is coated with latex microsphere-labeled novel coronavirus SARS-CoV-2 monoclonal antibody 1; immune nitrocellulose membrane is provided with a test line coated with novel coronavirus SARS-CoV-2 monoclonal antibody 2 and a quality control line coated with goat anti-mouse IgG polyclonal antibody. The present disclosure uses latex particles as labeled tracer, and uses antigen-antibody reaction and lateral chromatography to detect and analyze targets, having advantages of convenience and swift, and is convenient to be widely carried out in grass-roots community hospitals and health service centers.

traducir

USE OF PALMITOYLETHANOLAMIDE FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 INFECTIONS

NºPublicación: CA3148037A1 26/09/2022

Solicitante:

EPITECH GROUP S P A [IT]

Resumen de: CA3148037A1

The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

traducir

DETECTION DEVICE

NºPublicación: WO2022194296A1 22/09/2022

Solicitante:

ACON BIOTECH HANGZHOU CO LTD [CN]

CN_215575177_U

Resumen de: WO2022194296A1

Provided in the present invention is a detection device, which comprises a supporting plate, wherein a sample treatment pad, a reaction membrane and a water absorption pad are sequentially overlapped and adhered to the supporting plate from upstream to downstream, and a hydrophobic element is arranged at the downstream end of the water absorption pad of the detection device. The hydrophobic element, as a gripping area, can prevent further flow of a sample solution on the water absorption pad to an area, which is gripped by a user, of the detection device. The detection device of the present invention can effectively reduce the risk of infection of a user during sample inspection, especially the risk of infection of the user during sample inspection of infectious diseases, such as HBV, HIV, malaria, dengue fever, SARS and SARS-CoV-2.

traducir

RECOMBINANT MEASLES VIRUS

NºPublicación: WO2022195900A1 22/09/2022

Solicitante:

UNIV TOKYO [JP]

Resumen de: WO2022195900A1

The present invention provides: a recombinant measles virus useful as a live vaccine against COVID-19; and a vector used for producing the recombinant measles virus. That is, the present invention is a recombinant measles virus in which a gene encoding a protein of corona virus SARS-CoV-2 is inserted between the N gene region and the P gene region in a measles virus gene; the recombinant measles virus in which the protein is the spike protein of SARS-CoV-2 or a partial protein thereof; and DNA in which a gene encoding a protein of SARS-CoV-2 is inserted into the region from the base at position 1686 to the base at position 1694 in the nucleotide sequence represented by SEQ ID NO: 2.

traducir

BOVINE COLOSTRUM DERIVED ANTIBODIES AND USES THEREOF

NºPublicación: WO2022195455A1 22/09/2022

Solicitante:

ICOSAGEN CELL FACTORY OUE [EE]

Resumen de: WO2022195455A1

A method to produce immunoglobulin preparations against viral infection in humans spreading via respiratory route is provided. The method comprises the steps of immunizing dairy cows during a third trimester of at least a first gestation period with antigen proteins derived from at least one virus strain, collecting hyperimmune bovine colostrum comprising immunoglobulins effective against the antigen protein of various strains of the virus, preparing whey from the colostrum, isolating the immunoglobulin molecules from the whey, and preparing an immunoglobulin preparation for use as an intranasal treatment. One aspect of the invention is to produce SARS-CoV-2 spike protein specific hyperimmune bovine colostrum comprising a high concentration of anti-SARS-CoV-2 antibodies. An intranasal delivery system for diminishing risk of SARS-CoV-2 infections in humans is provided.

traducir

PEPTIDE AND METHOD FOR DIRECT ANALYSIS OF SARS-COV-2 IMMUNE RESPONSES

NºPublicación: WO2022195096A1 22/09/2022

Solicitante:

UNIV BERLIN CHARITE [DE]

WO_2022195120_A1

Resumen de: WO2022195096A1

The invention relates to a peptide comprising or consisting of an amino acid sequence FIEDLLFNKVT (SEQ ID NO 1) or a sequence of at least 80%, preferably at least 90%, sequence identity thereto. In embodiments, the peptide is of up to 25 amino acids, or 15-25 amino acids. The invention further relates to a nucleic acid molecule encoding the peptide of the invention, a solid phase comprising the peptide of the invention, an in vitro method for assessing the risk of a subject in developing a severe acute respiratory syndrome (SARS) or other adverse event or severe medical condition associated with SARS-CoV infection, comprising use of the peptide of the invention, the peptide of the invention for use in an immunogenic composition, such as a vaccine, a kit for performing the method, and a method for assessing the functional avidity of T cells for one or more antigens, employing the peptide of the invention.

traducir

SARS-CoV-2 vaccine

NºPublicación: AU2021221127A1 22/09/2022

Solicitante:

THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY
UNIV TEXAS
DARTMOUTH COLLEGE

WO_2021163365_A1

Resumen de: AU2021221127A1

SARS-CoV-2 S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the SARS-CoV-2 S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to SARS-CoV-2 S in a subject, for example, an immune response that inhibits SARS-CoV-2 infection in the subject.

traducir

Pharmaceutical use of ketoamide-based compound

NºPublicación: AU2021213137A1 22/09/2022

Solicitante:

SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES

TW_202130628_A

Resumen de: AU2021213137A1

Use of a class of ketoamide-based compounds, in particular, use of the ketoamide-based compound as represented by general formula A as a 2019 novel coronavirus (2019-nCov) 3CL protease inhibitor and/or human cathepsin L inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. The present invention also relates to use of pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection.

traducir

SYNTHETIC PLASMID DNA VACCINE EXPRESSING A CODON-OPTIMIZED SARS-COV-2 SPIKE PROTEIN AND METHODS FOR ITS USE

NºPublicación: US2022296701A1 22/09/2022

Solicitante:

KING ABDULAZIZ UNIVERISTY [SA]

US_2022296700_PA

Resumen de: US2022296701A1

A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 μg of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.

traducir

ROOM TEMPERATURE STABLE, SINGLE SHOT mRNA VACCINE FOR COVID-19

NºPublicación: US2022296728A1 22/09/2022

Solicitante:

CASTOR TREVOR PERCIVAL [US]

Resumen de: US2022296728A1

This disclosed technology relates to a new mRNA COVID-19 vaccine that is stable at room temperature, requires only one injection, and is less prone to patient hypersensitivity reactions. The vaccine is practical to deploy globally during vaccination campaigns for current and future coronavirus pandemics and other infectious diseases. The disclosed technology is a method and system for producing the vaccine, and also a double-encapsulated mRNA vaccine product. The method uses double nanoencapsulation of an mRNA vaccine, first in phospholipid nanosomes and then in biodegradable polymer nanospheres. The method may be carried out as a continuous flow, integral, or two-stage processes. The method and system use supercritical fluid technology for nanoencapsulating mRNA in a solvent free process that minimizes loss of potency and preserves antigenicity of the nanoencapsulated mRNA and eliminates residual organic solvents in the final product. The double-encapsulated mRNA vaccine product is stable at room temperature and can be administered in a single shot to humans.

traducir

Recombinant poxvirus based vaccine against SARS-CoV-2 virus

NºPublicación: AU2021226592A1 22/09/2022

Solicitante:

TONIX PHARMA LTD
UNIV ALBERTA

TW_202146428_A

Resumen de: AU2021226592A1

The invention relates in various aspects to a recombinant poxvirus comprising a nucleic acid encoding a SARS-CoV-2 virus protein, methods for producing such viruses and the use of such viruses. The recombinant poxviruses are well suited, among others, as protective virus vaccines against SARS-CoV-2 virus.

traducir

SYNTHETIC PLASMID DNA VACCINE EXPRESSING A CODON-OPTIMIZED SARS-COV-2 SPIKE PROTEIN AND METHODS FOR ITS USE

NºPublicación: US2022296700A1 22/09/2022

Solicitante:

KING ABDULAZIZ UNIVERISTY [SA]

US_2022296701_PA

Resumen de: US2022296700A1

A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 μg of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.

traducir

TREATMENT OR PREVENTION OF CORONAVIRIDAE INFECTION

NºPublicación: US2022296676A1 22/09/2022

Solicitante:

WATERSTONE PHARMACEUTICALS WUHAN CO LTD [CN]

JP_2022539640_PA

Resumen de: US2022296676A1

A method of treating or preventing a Coronaviridae infection in a subject comprising administrating a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the Coronaviridae comprises at least one selected from 2019-nCov virus, HCov 229E virus, SARS virus, MERS virus,

traducir

RAPID DIAGNOSTIC TEST COMPONENT

NºPublicación: US2022299508A1 22/09/2022

Solicitante:

DETECT INC [US]

WO_2022197635_PA

Resumen de: US2022299508A1

Provided herein, in some embodiments, are rapid diagnostic tests to detect one or more target nucleic acid sequences (e.g., a nucleic acid sequence of one or more pathogens). In some embodiments, the pathogens are viral, bacterial, fungal, parasitic, or protozoan pathogens, such as SARS-CoV-2 or an influenza virus. Further embodiments provide methods of detecting genetic abnormalities. Diagnostic tests comprising a sample-collecting component, one or more reagents (e.g., lysis reagents, nucleic acid amplification reagents), and a detection component (e.g., a component comprising a lateral flow assay strip) are provided.

traducir

OPTICAL COVID-19 DETECTION SYSTEM

NºPublicación: US2022299506A1 22/09/2022

Solicitante:

UNIV ILLINOIS [US]

WO_2022197853_A1

Resumen de: US2022299506A1

The disclosure provides example devices and methods for making and using the devices for rapid testing for the SARS-CoV-2 virus. The example device includes (a) a substrate coupled to a metal oxide layer, (b) a graphene layer coupled to the metal oxide layer, (c) a chemical or biochemical linker functionalized with the graphene layer, and (d) a plurality of SARS-CoV-2 receptors that are bound to the graphene layer via the chemical or biochemical linker, wherein the plurality of SARS-CoV-2 receptors comprise SARS-CoV-2 spike antibodies or SARS-CoV-2 spike proteins, where the graphene layer is configured to have a first phononic energy, when the plurality of SARS-CoV-2 receptors are unattached to target molecules, and a second phononic energy, when the plurality of SARS-CoV-2 receptors are attached to target molecules.

traducir

TEST COMBINATION PACKET AND TEST METHOD

NºPublicación: WO2022194286A1 22/09/2022

Solicitante:

ACON BIOTECH HANGZHOU CO LTD [CN]

CN_115112640_A

Resumen de: WO2022194286A1

The present invention provides a test combination packet and a test method for rapid sample test and analysis. The test combination packet comprises a test board and a sample extraction tube. The test combination packet and the test method provided by the present invention can improve the sensitivity of a product, play a positive role in suppressing the propagation of pathogens that cause respiratory diseases, and are suitable for rapid test of antigens and antibodies such as the currently popular novel coronavirus.

traducir

DIPHENYL ALKANE COMPOUND AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

NºPublicación: WO2022194136A1 22/09/2022

Solicitante:

INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCICENCES [CN]

Resumen de: WO2022194136A1

The invention belongs to the technical field of medicine. A soluble berberine-type quaternary ammonium alkaloid compound and the use thereof in preparing a drug are disclosed. In particular, disclosed are a compound as represented by general formula A and a compound that further may be represented specifically by general formulas I and I', a pharmaceutical composition thereof, a preparation method therefor, and the use thereof. The compounds of the present invention have significant activity in treating cardiovascular, cerebrovascular and blood system diseases, inflammatory diseases, febrile diseases, tumor diseases, autoimmune diseases and viral infectious diseases and complications thereof by inhibiting/reducing the activity of biological body pathological NO, iNOS, IL-6 and autoantibody levels, and inhibiting the activity of SARS-COV 2 virus RNA replication. The strength of the physical and chemical properties as well as the pharmacological function of the compounds of the present invention are superior to those of control drugs and related compounds, and can be used for preparing drugs for preventing, alleviating and/or treating cardiovascular, cerebrovascular and blood system diseases, inflammatory diseases, febrile diseases, tumor diseases, autoimmune diseases and viral infection diseases and complications thereof.

traducir

ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF FOR NOVEL CORONAVIRUS NUCLEOCAPSID PROTEIN, AND APPLICATION THEREOF

NºPublicación: WO2022193980A1 22/09/2022

Solicitante:

AMPSOURCE BIOPHARMA SHANGHAI INC [CN]

CN_112679605_A

Resumen de: WO2022193980A1

The present invention provides an antibody or an antigen-binding fragment thereof for novel coronavirus nucleocapsid protein, and an application thereof. The antibody is selected from any one of mAb6 antibody, mAb7 antibody, mAb8 antibody and mAb9 antibody; and the antibody is secreted by hybridoma cells having the accession numbers of CCTCC NO: C2020236, CCTCC NO: C2020237, CCTCC NO: C2020238 or CCTCC NO: C2020239. The presence of a novel coronavirus or an antigen thereof in an environmental sample and/or a biological sample can be detected by using the antibody. In addition, the present invention also provides a novel coronavirus detection kit prepared by using the antibody, capable of detecting the nucleocapsid protein in the early stage of infection, thereby providing a means to make the clinical detection of a novel coronavirus fast and precise.

traducir

BETA-LACTOGLOBULIN AND BETA-LACTOGLOBULIN DERIVED PEPTIDE PRODUCTS FROM GOAT MILK

NºPublicación: WO2022197266A1 22/09/2022

Solicitante:

MARMARA UNIV REKTORLUGU OZEL KALEM BIRIMI [TR]

Resumen de: WO2022197266A1

The present invention provides the beta-lactoglobulin protein and beta-lactoglobulin derived bioactive peptides from the whey fraction of goat milk and antiviral uses thereof, is preventive from infectious diseases and have effects of disease prevention and immune system by affecting on the entry gates of other types of coronaviruses [SARS CoV 2 besides SARS CoV and MERS]. Within the scope of the invention, ALPMHIR (SEQ ID NO:1), GLDIQK (SEQ ID NO:2), TPEVDK (SEQ ID NO:3), IPAVFK (SEQ ID NO:4), EALEK (SEQ ID NO:5) and IIAEK (SEQ ID NO:6) peptides are presented for use in the prevention and also potential treatment of infectious diseases, particularly COVID-19 (SARS-CoV-2).

traducir

INFLUENZA VIRUS VECTOR-BASED NOVEL CORONAVIRUS VACCINE AND PREPARATION METHOD THEREFOR

NºPublicación: WO2022193553A1 22/09/2022

Solicitante:

GUANGZHOU N BIOMED LTD [CN]

CN_113069540_A

Resumen de: WO2022193553A1

Disclosed in the present invention are an influenza virus vector-based novel coronavirus vaccine and a preparation method therefor. The vaccine can efficiently express two antigens, i.e., an HA antigen of the vaccine and an exogenous SC2R1 antigen, such that the vaccine can induce immune response of the two antigens to achieve the purpose of preventing influenza viruses and novel coronaviruses at the same time, and reduce the influences of two infectious diseases, i.e., influenza and novel coronaviruses, on the social economy, etc. Moreover, an influenza vaccine can be prepared and produced on a large scale on the basis of existing mature influenza platform technologies, and the influenza vaccine has a long use history and good safety.

traducir

OPTICAL COVID-19 DETECTION SYSTEM

NºPublicación: WO2022197853A1 22/09/2022

Solicitante:

UNIV ILLINOIS [US]

US_2022299506_PA

Resumen de: WO2022197853A1

The disclosure provides example devices and methods for making and using the devices for rapid testing for the SARS-CoV-2 virus. The example device includes (a) a substrate coupled to a metal oxide layer, (b) a graphene layer coupled to the metal oxide layer, (c) a chemical or biochemical linker functionalized with the graphene layer, and (d) a plurality of SARS-CoV-2 receptors that are bound to the graphene layer via the chemical or biochemical linker, wherein the plurality of SARS-CoV-2 receptors comprise SARS-CoV-2 spike antibodies or SARS-CoV-2 spike proteins, where the graphene layer is configured to have a first phononic energy, when the plurality of SARS-CoV-2 receptors are unattached to target molecules, and a second phononic energy, when the plurality of SARS-CoV-2 receptors are attached to target molecules.

traducir

THERAPEUTIC USE OF SARS-COV-2 MRNA DOMAIN VACCINES

NºPublicación: WO2022197624A1 22/09/2022

Solicitante:

MODERNATX INC [US]

Resumen de: WO2022197624A1

The disclosure describes coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The RNA vaccines encode domains and subunits of coronavirus.

traducir

COMPOSITION FOR USE IN THE TREATMENT OF COVID-19

NºPublicación: WO2022195558A1 22/09/2022

Solicitante:

UNIV KING ABDULLAH SCI & TECH [SA]

Resumen de: WO2022195558A1

Compositions and methods for treating a SARS-CoV-2 infection are provided. The disclosed compositions and methods are based on an interaction pathways and inhibition of serine 206 phosphorylation of the Nucleocapsid (N) protein of SARS-CoV-2. The compositions include one of more compounds capable of inhibition of phosphorylation of the Nucleocapsid serine 206. The amount of one or more compounds can be effective to, for example, reduce viral replication, reduce one or more symptoms of a disease, disorder, or illness associated with virus, or a combination thereof. Method for identifying a subject as having an elevated risk of developing one or more symptoms associated with severe COVID-19 are also provided.

traducir

INDUCTION OF IMMUNITY TO SARS-COV-2 IN CHILDREN

NºPublicación: WO2022197209A1 22/09/2022

Solicitante:

FEDERAL STATE BUDGETARY INSTITUTION NATIONAL RES CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTE [RU]

RU_2761904_C1

Resumen de: WO2022197209A1

Group of invention relates to biotechnology, immunology and virology. Described is the use of an agent containing expression vector based on strain human adenovirus serotype 26 or human adenovirus serotype 5, in which E1 and E3 regions are deleted, with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or simian adenovirus serotype 25, in which E1 and E3 regions are deleted with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 or contains only component 2 for for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.

traducir

COMPOSITIONS AND METHODS FOR TARGETING INFLAMMATORY OR ARCTIVATED CELLS AND TREATING OR AMELIORATING INFLAMMATORY CONDITIONS AND PAIN

Nº publicación: WO2022198073A1 22/09/2022

Solicitante:

UNIV CALIFORNIA [US]

Resumen de: WO2022198073A1

Provided are methods for modification of amino acid sequence and increasing levels of expression of ApoA-I Binding Protein to treat: a neuropathic pain, a CNS inflammation, an allodynia, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy, a neurodegeneration, including for example, a neurodegenerative disease or condition such as Alzheimer's disease, a hyperalgesia, primary headaches such as migraines and cluster headaches, glaucoma or other inflammatory diseases of the eye, lung inflammation, asthma, HIV infection, vascular inflammation, atherosclerosis and cardiovascular disease. Provided are methods comprising administering pharmaceutical compositions comprising a recombinantly modified APOA1BP polypeptide to treat a neuropathic pain, an allodynia, a hyperalgesia, a neurodegenerative disease, a primary headache such as a migraine, glaucoma, lung inflammation and asthma, acute respiratory distress syndrome (ARDS), sepsis, viral infection, including influenza, coronavirus (for example, COVID-19) or HIV infection, or its comorbidities, and/or vascular inflammation, atherosclerosis and cardiovascular disease.

traducir

Página1 de 15 nextPage por página

punteroimgVolver